Surrozen (SRZN) CEO Craig Parker Buys $13K of Stock

Craig Parker, the CEO of Surrozen, Inc., recently bought 1,622 shares of the company at an average price of $8.11 each, totaling $13,154.42. This purchase took place on June 15, 2026, and was not part of a pre-planned trading program.

Other Institutional Activity in Surrozen

Several institutional investors have adjusted their positions in Surrozen recently. COLUMN GROUP LLC increased its holdings by 65,600 shares, bringing its total to 1,916,950 shares valued at about $55.8 million. TCG CROSSOVER MANAGEMENT, LLC acquired 1,473,101 shares, resulting in a total of the same amount, worth approximately $42.9 million. BOXER CAPITAL MANAGEMENT, LLC significantly boosted its stake by 350,168 shares, ending with 766,318 shares valued at $22.3 million. Meanwhile, STEMPOINT CAPITAL LP reduced its holdings by 94,127 shares, leaving it with 525,639 shares worth around $13.5 million.

Surrozen, Inc. Stock Up 37.5%

Shares of NasdaqCM:SRZN traded near $23.14. Surrozen, Inc. has a market cap of approximately $264.1 million. The company isn't currently profitable, so it has no meaningful P/E ratio. The stock's 52-week low is $8.00 and its high is $35.00, with a 50-day moving average of $27.95 and a 200-day moving average of $21.21. Surrozen has a current ratio of 11.91 and a quick ratio of 11.7, showing strong liquidity.

Recent Earnings

Surrozen reported revenue of $7.49 million, showing a modest growth rate of 4.09%. Despite this, the company has a net margin of 0.0%, reflecting ongoing challenges in achieving profitability. The next earnings report is expected on May 9, 2025.

Insider Buying and Selling at Surrozen, Inc.

On June 15, 2026, several insiders at Surrozen made notable purchases. Chief Operating Officer Charles Williams bought 1,666 shares at $8.11 each. CEO Craig Parker acquired 1,622 shares at the same price. Chief Financial Officer Andrew Pedrum Maleki purchased 607 shares at $19.01 each. Executive Vice President of Research Yang Li also bought 1,666 shares at $8.11.

Analysts Set New Price Targets

On May 7, 2026, HC Wainwright & Co. maintained its 'buy' rating on Surrozen with a price target of $44.00. Cantor Fitzgerald initiated coverage with a 'buy' rating and a $40.00 price target on February 19, 2026. The consensus among analysts is a 'buy' recommendation, with an average target price of $42.50 based on four analyst opinions.

About Surrozen, Inc.

Surrozen, Inc. is a biotechnology company based in South San Francisco, California. Specializing in the discovery and development of product candidates to modulate the Wnt pathway for tissue repair, the company targets various disease areas such as eye, intestine, liver, and lung diseases. Surrozen's key products include SZN-814, aimed at treating conditions like diabetic macular edema and wet AMD. Founded in 2015, the company employs 44 people and is led by CEO Craig Parker.

Bottom Line

Craig Parker's recent share purchase in Surrozen underscores his confidence in the company's direction. The firm continues to be a point of interest for institutional investors and analysts alike, with several maintaining positive ratings and price targets. As Surrozen works towards profitability, investors will be closely watching its financial performance and strategic developments.